In praise of model organisms by Petsko, Gregory A
One of the many things I have against former Republican 
Vice-Presidential candidate Sarah Palin is not her lack of 
intelligence - she may in fact be intelligent, although she 
doesn’t act like it (but then, I know a number of intelligent 
people who behave that way). But if she isn’t very smart, 
that’s not her fault. We all have to play the cards we’re 
dealt. What I do have against Sarah Palin is her ignorance, 
because she has had ample opportunity to do something 
about that, and hasn’t bothered even to try. In my view, 
she is not just ignorant; she’s willfully ignorant, which I 
find inexcusable.
Anything that might disturb her comfortable, distorted 
view of reality is not just ignored - it’s often ridiculed. In 
October  2008,  in  a  speech  she  gave  on  autism  and 
disabilities, she had this to say:
“This is a matter of how we prioritize the money 
that  we  spend.  We’ve  got  a  three  trillion  dollar 
budget,  and  Congress  spends  some  18  billion 
dollars  a  year  on  earmarks  for  political  pet 
projects. That’s more than the shortfall to fully fund 
the IDEA [Individuals with Disabilities Education 
Act]. And where does a lot of that earmark money 
end up? It goes to projects having little or nothing 
to  do  with  the  public  good  -  things  like  fruit  fly 
research in Paris, France... I kid you not. ”
The quote doesn’t do justice to the mocking inflection 
of her voice as she says ‘fruit fly research’, but there are 
ample recordings floating around the Web if you care to 
hear it.
Of course, one retort might be that the average fruit fly 
may  well  be  better  informed  than  Sarah  Palin,  but  ad 
feminem  attacks  shouldn’t  win  any  argument,  and 
besides,  some  targets  are  just  too  easy.  No,  the  real 
problem  with  her  remark  isn’t  that  it  comes  from  a 
clueless politician; it’s that there is disturbing evidence 
that the same sentiment may be taking hold among those 
who set the direction of scientific research in the US.
I know what you’re probably thinking: “Wait a minute. I 
thought the direction of scientific research in the US was 
set  by  peer  review  of  research  applications.  Are  you 
saying  that  research  scientists  are  clueless  about  the 
importance of the fruit fly as a model organism?”
No, I’m not. I think most practicing biologists under-
stand  very  well  the  vital  role  that  model  organism 
research has had in the development of their field, and 
should continue to have in the future. But if you think 
that the direction of scientific research is still set by open 
competition  in  grant  review  panels,  you  should  think 
again.
One of the most disturbing recent trends in the politics 
of scientific funding has been the creeping hegemony of 
top-down  prioritization.  When  Vannevar  Bush  created 
the  modern  edifice  of  government-supported  basic 
research  in  the  1950s  (before  that  time  science  was 
largely  supported  by  small  grants  from  one’s  home 
institution or funds from industry), he envisioned that 
the direction of such research would be set by curiosity-
driven, investigator-initiated research proposals compet-
ing for funding in open peer-review panels. And for more 
than  40  years,  with  occasional  hiccups  (for  example, 
President Nixon’s War on Cancer), that was the case. I 
think most objective observers would concur that, as an 
engine  for  driving  innovation,  the  system  worked 
amazingly  well  -  especially  compared  with  more  top-
down, managed science structures such as those in Japan 
and many European countries.
But then two things happened. One was the increasing 
clamor  by  patient  advocacy  groups  for  biomedical 
delivery on the promises that had been made to justify 
the big increases in funding during the previous decades. 
Now, I happen to believe that there have actually been far 
more successes than the public are aware of - we simply 
have done a terrible job of getting those stories across. 
But  this  is  clearly  one  case  where  perception  trumps 
reality. And as science administrators came under fire by 
impatient groups of patients, they naturally responded by 
trying to take more control of the scientific enterprise 
into their own hands, so it could be steered towards more 
direct pay-offs.
The  other  disruptive  event  was  the  success  of  the 
human  genome  project.  By  ‘success’  I  don’t  mean 
scientifically - though it certainly was successful that way.  © 2010 BioMed Central Ltd
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© 2011 BioMed Central LtdI mean its success in making anyone connected with it - 
the  scientists  who  led  it,  and  the  bureaucrats  who 
supported  it  -  famous  and  in  advancing  their  careers. 
Plus, you will recall that the human genome project was 
initiated  by  a  small  group  of  scientists  against  the 
objection of many of their colleagues that it would divert 
funds  away  from  small  basic  research  projects.  The 
lessons  that  were  learned  was  that  it  paid  to  set  the 
direction  of  research  from  the  top  down  and  that  big 
science programs were a rising tide that could lift, if not 
all boats, then certainly the boats that were tied to them.
Naturally,  the  human  genome  project  led  to  other 
human fill-in-the-blanks-omics projects. Equally naturally, 
these were paraded before the public as examples of how 
the  biomedical  research  establishment  was  trying  to 
satisfy their demand for results. And so, inexorably over 
the past 15 years, it has become easier to get research 
that  is  closely  related  to  human  biology  and  human 
disease  funded  than  research  that  is  more  distantly 
related.
Among the casualties of this trend is model organism 
research, and not just in the halls of the funding agencies. 
One of the outstanding examples of the success of model 
organism approaches in recent years has been the work 
on models for neurodegenerative diseases. The difficulties 
in  working  directly  with  the  human  central  nervous 
system vanish when one uses flies or worms or fish; and 
the intracellular processes involved in neurodegeneration 
can be modeled down to some extent down to unicellular 
eukaryotes like yeast. Drug screens in yeast and screens 
for disease modifier genes in yeast, worms, flies, and fish 
have  yielded  results  that  translate  cleanly  to  disease 
models in mice and rats. There are potential therapeutics 
entering animal toxicity studies, prior to human clinical 
trials, for devastating disorders like Parkinson’s disease 
that  were  first  identified  from  screens  in  much  lower 
organisms.  And  most  of  the  fundamental  intracellular 
pathways that are involved in numerous human diseases 
were first identified in such organisms and continue to be 
identified first in such models - a recent example being 
autophagy,  which  was  discovered  and  characterized  in 
yeast.
Despite numerous examples of the enormous value of 
model organism research, many scientists and scientific 
administrators seem to think that nothing lower than a 
mouse  is  suitable  for  cutting-edge  biology  anymore.  I 
have  seen  reviews  of  submitted  papers  in  which  the 
referee  clearly  does  not  believe  it  is  possible  to  gain 
insight into human diseases from studies in yeast models - 
never  mind  more  than  20  years  of  evidence  to  the 
contrary.  Grant  applications  to  support  such  research 
also have a similar gauntlet to run.
The  current  love  affair  with  mouse  models  is 
particularly  troubling  to  me  because  it’s  not  clear  that 
mice  are  all  that  good  as  a  model  for  many  human 
diseases.  Why  would  one  even  expect  that  a  relatively 
genetically homogeneous mouse population, raised in a 
sterile environment, recapitulates salient features of the 
mongrel-like, flora- and fauna-infested human race? An 
alarmingly high percentage of genes produce no pheno-
type  when  they  are  knocked  out  in  a  mouse.  Mouse 
models  for  neurodegenerative  diseases  are  notoriously 
bad: in almost no case is the full range of human patho-
logy,  including  histopathology,  faithfully  reproduced 
(perhaps because mice simply don’t live long enough), so 
it’s far from certain that one learns as much from them as 
from  studies  in  simpler,  less-expensive  organisms  for 
which a wider range of techniques are available.
Plus, there is the fact that human disease models are 
suspiciously  easy  to  cure  in  mice.  Most  non-biological 
drugs that are taken into human clinical trials fail not in 
Phase 1, where toxicity is assessed, but in Phase 2, where 
efficacy is evaluated, suggesting that mouse models for 
many human diseases, which are the most common ones 
used to evaluate efficacy in pre-clinical trials, are woefully 
inadequate. (There is some hope that rat models may be 
better for some neurological disorders, but it’s too early 
to tell yet.)
Basic research discoveries, which are the wellspring of 
major advances in medicine and other applied areas of 
science,  are  likely  to  come  from  research  in  simple 
systems for the foreseeable future, which makes the rush 
to displace them with mammalian models hard to justify. 
(I’m not trying to trash all mammalian models here; one 
will  always  have  need  for  both.)  We  need  to  keep 
reminding  the  powers  that  be,  who  seem  hell-bent  on 
setting the direction of research in the US, that funda-
mental  work  in  lower  organisms  remains  incredibly 
important.
If you want an example to show them, a recent issue of 
Nature  provides  a  good  one.  The  cover  articles  are 
reports of two breakthrough discoveries in melanoma - a 
deadly and hard-to-treat skin cancer - that were made by 
studying zebrafish. It has been known for some time that 
the  most  common  mutation  in  human  melanoma  is 
BRAF(V600E),  which  activates  the  oncogenic  protein 
kinase  BRAF;  however,  such  mutations  also  occur  in 
benign lesions, highlighting the importance of multiple 
causative loci, as Hannahan and Weinberg pointed many 
years ago out must be true for most, if not all, cancers. To 
pinpoint one such mutation, Ceol et al. (Nature 471:513-
517, 2011) developed an assay to test candidate genes in 
transgenic  zebrafish  expressing  BRAF(V600E),  the 
equivalent of a classic synthetic lethal screen in genetics. 
The study identified SETDB1, which encodes a histone 
methyltransferase,  as  the  gene  harboring  the  second 
genetic lesion (an amplification). Further analysis showed 
that increased levels of SETDB1 dysregulated a number 
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melanoma.  In  the  second  report,  White  et  al.  (Nature 
471:518-522,  2011)  used  zebrafish  embryos  to  identify 
the  transcriptional  events  that  occur  when  BRAF  is 
activated.  Because  melanocytes  derive  from  the  neural 
crest  during  development,  a  chemical  genetics  screen 
was performed for compounds that would suppress the 
neural crest lineage during zebrafish development; any 
hits  were  then  tested  for  their  effects  on  melanoma 
models. Inhibitors of the enzyme dihydrooritate dehydro-
genase led to an almost complete abrogation of neural 
crest development in the fish, and to a reduction in self-
renewal  of  mammalian  neural  crest  stem  cells.  These 
same inhibitors markedly decreased melanoma growth in 
vitro and in mouse xenograft models.
It may be that both of these studies could have been 
carried out with equal success in human cell culture or 
mouse studies, but they weren’t, and it’s pretty certain 
that they could not have been carried out as efficiently, if 
at all. The progression from the model organism studies 
in fish, which identified novel pathways and targets, to 
the  follow-up  work  in  mammals  and  mammalian  cells 
can be extremely powerful, as shown here, but will it be 
possible to obtain support for such a progression in the 
future  if  only  work  in  higher  organisms  is  deemed 
relevant to human disease?
Obviously,  things  have  not  gone  so  far  -  yet  -  that 
research on model organisms is impossible to get funded 
or published. But I don’t like the trend, and I think it will 
take constantly reminding our administrators - and our 
peers  -  of  the  value  of  such  research  to  combat  the 
encroaching belief, which is probably not even true for 
behavior, that the proper study of mankind is man - or at 
least mice and men.
If science administrators adopt the dogma that human 
biology can be uncovered only by studies on mammalian 
cells or on organisms at least as complex as a mouse; if 
the  people  who  allocate  research  funds  are  convinced 
that human diseases cannot be modeled effectively in less 
complex,  but  more  genetically  and  biochemically  trac-
table, organisms; if scientists forget the grand unity of 
biology that underlies all of the great advances that have 
been  made  by  studying  simple  systems  ranging  from 
bacteriophage to zebrafish; if we all succumb, in other 
words, to a Sarah Palin-esque view of the world, then our 
ability  to  innovate  will  slow  to  a  worm-like  crawl;  the 
forces of ignorance will continue to rise like yeast; we will 
be swimming upstream in our attempt to bring the fruits 
of  genomics  to  the  public;  and  projects  that  have 
everything to do with the public good will die like flies. I 
kid you not.
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